| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.851 | 0.005 | 0.851 | Angiogenesis inhibitor | 0.851 0.005 DBMET03266 0.851 0.005 DBMET03267 0.851 0.005 DBMET03268 0.851 0.005 DBMET03269 | ||
| 0.699 | 0.005 | 0.699 | Immunomodulator | 0.699 0.005 DBMET03266 0.699 0.005 DBMET03267 0.699 0.005 DBMET03268 0.699 0.005 DBMET03269 | ||
| 0.657 | 0.003 | 0.657 | Topoisomerase II alpha inhibitor | 0.657 0.003 DBMET03266 0.657 0.003 DBMET03267 0.657 0.003 DBMET03268 0.657 0.003 DBMET03269 | ||
| 0.649 | 0.039 | 0.649 | Apoptosis agonist | 0.649 0.039 DBMET03266 0.649 0.039 DBMET03267 0.649 0.039 DBMET03268 0.649 0.039 DBMET03269 | ||
| 0.512 | 0.013 | 0.512 | DNA synthesis inhibitor | 0.512 0.013 DBMET03266 0.512 0.013 DBMET03267 0.512 0.013 DBMET03268 0.512 0.013 DBMET03269 | ||
| 0.478 | 0.005 | 0.478 | Phosphodiesterase inhibitor | 0.478 0.005 DBMET03266 0.478 0.005 DBMET03267 0.478 0.005 DBMET03268 0.478 0.005 DBMET03269 | ||
| 0.432 | 0.006 | 0.432 | Alkylator | 0.432 0.006 DBMET03266 0.432 0.006 DBMET03267 0.432 0.006 DBMET03268 0.432 0.006 DBMET03269 | ||
| 0.43 | 0.009 | 0.43 | Topoisomerase II inhibitor | 0.43 0.009 DBMET03266 0.43 0.009 DBMET03267 0.43 0.009 DBMET03268 0.43 0.009 DBMET03269 | ||
| 0.353 | 0.003 | 0.353 | Phosphodiesterase II inhibitor | 0.353 0.003 DBMET03266 0.353 0.003 DBMET03267 0.353 0.003 DBMET03268 0.353 0.003 DBMET03269 | ||
| 0.344 | 0.003 | 0.344 | Phosphodiesterase 2A inhibitor | 0.344 0.003 DBMET03266 0.344 0.003 DBMET03267 0.344 0.003 DBMET03268 0.344 0.003 DBMET03269 | ||
| 0.349 | 0.041 | 0.349 | DNA damaging | 0.349 0.041 DBMET03266 0.349 0.041 DBMET03267 0.349 0.041 DBMET03268 0.349 0.041 DBMET03269 | ||
| 0.375 | 0.073 | 0.375 | GABA C receptor rho-3 antagonist | 0.375 0.073 DBMET03266 0.375 0.073 DBMET03267 0.375 0.073 DBMET03268 0.375 0.073 DBMET03269 | ||
| 0.313 | 0.016 | 0.313 | Protein kinase (CK1) inhibitor | 0.313 0.016 DBMET03266 0.313 0.016 DBMET03267 0.313 0.016 DBMET03268 0.313 0.016 DBMET03269 | ||
| 0.296 | 0.008 | 0.296 | MAP kinase kinase 3 inhibitor | 0.296 0.008 DBMET03266 0.296 0.008 DBMET03267 0.296 0.008 DBMET03268 0.296 0.008 DBMET03269 | ||
| 0.287 | 0.012 | 0.287 | Heat shock protein 90 antagonist | 0.287 0.012 DBMET03266 0.287 0.012 DBMET03267 0.287 0.012 DBMET03268 0.287 0.012 DBMET03269 | ||
| 0.297 | 0.044 | 0.297 | Antimitotic | 0.297 0.044 DBMET03266 0.297 0.044 DBMET03267 0.297 0.044 DBMET03268 0.297 0.044 DBMET03269 | ||
| 0.245 | 0.026 | 0.245 | Polo-like kinase-3 inhibitor | 0.245 0.026 DBMET03266 0.245 0.026 DBMET03267 0.245 0.026 DBMET03268 0.245 0.026 DBMET03269 | ||
| 0.328 | 0.11 | 0.328 | MAP kinase kinase 6 inhibitor | 0.328 0.11 DBMET03266 0.328 0.11 DBMET03267 0.328 0.11 DBMET03268 0.328 0.11 DBMET03269 | ||
| 0.265 | 0.051 | 0.265 | Anticonvulsant | 0.265 0.051 DBMET03266 0.265 0.051 DBMET03267 0.265 0.051 DBMET03268 0.265 0.051 DBMET03269 | ||
| 0.192 | 0.006 | 0.192 | Phosphodiesterase 5A inhibitor | 0.192 0.006 DBMET03266 0.192 0.006 DBMET03267 0.192 0.006 DBMET03268 0.192 0.006 DBMET03269 | ||
| 0.21 | 0.026 | 0.21 | Cell wall synthesis inhibitor | 0.21 0.026 DBMET03266 0.21 0.026 DBMET03267 0.21 0.026 DBMET03268 0.21 0.026 DBMET03269 | ||
| 0.179 | 0.007 | 0.179 | Phosphodiesterase V inhibitor | 0.179 0.007 DBMET03266 0.179 0.007 DBMET03267 0.179 0.007 DBMET03268 0.179 0.007 DBMET03269 | ||
| 0.211 | 0.062 | 0.211 | I kappa B kinase epsilon inhibitor | 0.211 0.062 DBMET03266 0.211 0.062 DBMET03267 0.211 0.062 DBMET03268 0.211 0.062 DBMET03269 | ||
| 0.151 | 0.005 | 0.151 | Glutamate (mGluR group II) agonist | 0.151 0.005 DBMET03266 0.151 0.005 DBMET03267 0.151 0.005 DBMET03268 0.151 0.005 DBMET03269 | ||
| 0.147 | 0.006 | 0.147 | Phosphodiesterase X inhibitor | 0.147 0.006 DBMET03266 0.147 0.006 DBMET03267 0.147 0.006 DBMET03268 0.147 0.006 DBMET03269 | ||
| 0.147 | 0.006 | 0.147 | Phosphodiesterase 10A inhibitor | 0.147 0.006 DBMET03266 0.147 0.006 DBMET03267 0.147 0.006 DBMET03268 0.147 0.006 DBMET03269 | ||
| 0.144 | 0.005 | 0.144 | Glutamate (mGluR2) agonist | 0.144 0.005 DBMET03266 0.144 0.005 DBMET03267 0.144 0.005 DBMET03268 0.144 0.005 DBMET03269 | ||
| 0.292 | 0.17 | 0.292 | Cyclophilin D inhibitor | 0.292 0.17 DBMET03266 0.292 0.17 DBMET03267 0.292 0.17 DBMET03268 0.292 0.17 DBMET03269 | ||
| 0.128 | 0.026 | 0.128 | Polo-like kinase-1 inhibitor | 0.128 0.026 DBMET03266 0.128 0.026 DBMET03267 0.128 0.026 DBMET03268 0.128 0.026 DBMET03269 | ||
| 0.198 | 0.102 | 0.198 | RNA-directed DNA polymerase inhibitor | 0.198 0.102 DBMET03266 0.198 0.102 DBMET03267 0.198 0.102 DBMET03268 0.198 0.102 DBMET03269 | ||
| 0.101 | 0.007 | 0.101 | Stearoyl-CoA desaturase inhibitor | 0.101 0.007 DBMET03266 0.101 0.007 DBMET03267 0.101 0.007 DBMET03268 0.101 0.007 DBMET03269 | ||
| 0.1 | 0.014 | 0.1 | Phosphodiesterase VIII inhibitor | 0.1 0.014 DBMET03266 0.1 0.014 DBMET03267 0.1 0.014 DBMET03268 0.1 0.014 DBMET03269 | ||
| 0.105 | 0.022 | 0.105 | Glutamate (mGluR) agonist | 0.105 0.022 DBMET03266 0.105 0.022 DBMET03267 0.105 0.022 DBMET03268 0.105 0.022 DBMET03269 | ||
| 0.09 | 0.009 | 0.09 | Nicotinic acid receptor 1 agonist | 0.09 0.009 DBMET03266 0.09 0.009 DBMET03267 0.09 0.009 DBMET03268 0.09 0.009 DBMET03269 | ||
| 0.11 | 0.03 | 0.11 | Glutamate (mGluR) antagonist | 0.11 0.03 DBMET03266 0.11 0.03 DBMET03267 0.11 0.03 DBMET03268 0.11 0.03 DBMET03269 | ||
| 0.094 | 0.018 | 0.094 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.094 0.018 DBMET03266 0.094 0.018 DBMET03267 0.094 0.018 DBMET03268 0.094 0.018 DBMET03269 | ||
| 0.076 | 0.005 | 0.076 | Parathyroid hormone antagonist | 0.076 0.005 DBMET03266 0.076 0.005 DBMET03267 0.076 0.005 DBMET03268 0.076 0.005 DBMET03269 | ||
| 0.145 | 0.075 | 0.145 | Hemostatic | 0.145 0.075 DBMET03266 0.145 0.075 DBMET03267 0.145 0.075 DBMET03268 0.145 0.075 DBMET03269 | ||
| 0.133 | 0.064 | 0.133 | Protein kinase (CK1) delta inhibitor | 0.133 0.064 DBMET03266 0.133 0.064 DBMET03267 0.133 0.064 DBMET03268 0.133 0.064 DBMET03269 | ||
| 0.29 | 0.225 | 0.29 | Antiinflammatory | 0.29 0.225 DBMET03266 0.29 0.225 DBMET03267 0.29 0.225 DBMET03268 0.29 0.225 DBMET03269 | ||
| 0.125 | 0.062 | 0.125 | DNA repair enzyme inhibitor | 0.125 0.062 DBMET03266 0.125 0.062 DBMET03267 0.125 0.062 DBMET03268 0.125 0.062 DBMET03269 | ||
| 0.148 | 0.088 | 0.148 | Heat shock protein 90 alpha antagonist | 0.148 0.088 DBMET03266 0.148 0.088 DBMET03267 0.148 0.088 DBMET03268 0.148 0.088 DBMET03269 | ||
| 0.091 | 0.034 | 0.091 | Polo-like kinase-2 inhibitor | 0.091 0.034 DBMET03266 0.091 0.034 DBMET03267 0.091 0.034 DBMET03268 0.091 0.034 DBMET03269 | ||
| 0.093 | 0.038 | 0.093 | Phosphodiesterase 3A inhibitor | 0.093 0.038 DBMET03266 0.093 0.038 DBMET03267 0.093 0.038 DBMET03268 0.093 0.038 DBMET03269 | ||
| 0.111 | 0.057 | 0.111 | MAP kinase kinase kinase inhibitor | 0.111 0.057 DBMET03266 0.111 0.057 DBMET03267 0.111 0.057 DBMET03268 0.111 0.057 DBMET03269 | ||
| 0.084 | 0.03 | 0.084 | Adenosine A2a receptor antagonist | 0.084 0.03 DBMET03266 0.084 0.03 DBMET03267 0.084 0.03 DBMET03268 0.084 0.03 DBMET03269 | ||
| 0.142 | 0.088 | 0.142 | Cyclin-dependent kinase 8 inhibitor | 0.142 0.088 DBMET03266 0.142 0.088 DBMET03267 0.142 0.088 DBMET03268 0.142 0.088 DBMET03269 | ||
| 0.086 | 0.032 | 0.086 | Adenosine A2 receptor antagonist | 0.086 0.032 DBMET03266 0.086 0.032 DBMET03267 0.086 0.032 DBMET03268 0.086 0.032 DBMET03269 | ||
| 0.106 | 0.054 | 0.106 | GABA C receptor rho-1 antagonist | 0.106 0.054 DBMET03266 0.106 0.054 DBMET03267 0.106 0.054 DBMET03268 0.106 0.054 DBMET03269 | ||
| 0.088 | 0.038 | 0.088 | Glutamate dehydrogenase inhibitor | 0.088 0.038 DBMET03266 0.088 0.038 DBMET03267 0.088 0.038 DBMET03268 0.088 0.038 DBMET03269 | ||
| 0.261 | 0.213 | 0.261 | 5 Hydroxytryptamine release inhibitor | 0.261 0.213 DBMET03266 0.261 0.213 DBMET03267 0.261 0.213 DBMET03268 0.261 0.213 DBMET03269 | ||
| 0.06 | 0.014 | 0.06 | Benzodiazepine inverse agonist | 0.06 0.014 DBMET03266 0.06 0.014 DBMET03267 0.06 0.014 DBMET03268 0.06 0.014 DBMET03269 | ||
| 0.061 | 0.02 | 0.061 | Adenosine deaminase inhibitor | 0.061 0.02 DBMET03266 0.061 0.02 DBMET03267 0.061 0.02 DBMET03268 0.061 0.02 DBMET03269 | ||
| 0.138 | 0.098 | 0.138 | Growth hormone agonist | 0.138 0.098 DBMET03266 0.138 0.098 DBMET03267 0.138 0.098 DBMET03268 0.138 0.098 DBMET03269 | ||
| 0.096 | 0.057 | 0.096 | Alpha 2d adrenoreceptor antagonist | 0.096 0.057 DBMET03266 0.096 0.057 DBMET03267 0.096 0.057 DBMET03268 0.096 0.057 DBMET03269 | ||
| 0.05 | 0.013 | 0.05 | Protein kinase (CK1) epsilon inhibitor | 0.05 0.013 DBMET03266 0.05 0.013 DBMET03267 0.05 0.013 DBMET03268 0.05 0.013 DBMET03269 | ||
| 0.079 | 0.045 | 0.079 | Adenosine A3 receptor antagonist | 0.079 0.045 DBMET03266 0.079 0.045 DBMET03267 0.079 0.045 DBMET03268 0.079 0.045 DBMET03269 | ||
| 0.159 | 0.128 | 0.159 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.159 0.128 DBMET03266 0.159 0.128 DBMET03267 0.159 0.128 DBMET03268 0.159 0.128 DBMET03269 | ||
| 0.083 | 0.053 | 0.083 | Phosphodiesterase XI inhibitor | 0.083 0.053 DBMET03266 0.083 0.053 DBMET03267 0.083 0.053 DBMET03268 0.083 0.053 DBMET03269 | ||
| 0.083 | 0.053 | 0.083 | Phosphodiesterase 11A inhibitor | 0.083 0.053 DBMET03266 0.083 0.053 DBMET03267 0.083 0.053 DBMET03268 0.083 0.053 DBMET03269 | ||
| 0.067 | 0.037 | 0.067 | Carbamoyl phosphate synthetase inhibitor | 0.067 0.037 DBMET03266 0.067 0.037 DBMET03267 0.067 0.037 DBMET03268 0.067 0.037 DBMET03269 | ||
| 0.074 | 0.045 | 0.074 | Benzodiazepine agonist | 0.074 0.045 DBMET03266 0.074 0.045 DBMET03267 0.074 0.045 DBMET03268 0.074 0.045 DBMET03269 | ||
| 0.093 | 0.067 | 0.093 | Lanosterol 14 alpha demethylase inhibitor | 0.093 0.067 DBMET03266 0.093 0.067 DBMET03267 0.093 0.067 DBMET03268 0.093 0.067 DBMET03269 | ||
| 0.156 | 0.13 | 0.156 | MAP kinase kinase 5 inhibitor | 0.156 0.13 DBMET03266 0.156 0.13 DBMET03267 0.156 0.13 DBMET03268 0.156 0.13 DBMET03269 | ||
| 0.063 | 0.038 | 0.063 | Phosphodiesterase 1B inhibitor | 0.063 0.038 DBMET03266 0.063 0.038 DBMET03267 0.063 0.038 DBMET03268 0.063 0.038 DBMET03269 | ||
| 0.063 | 0.038 | 0.063 | Biliverdin reductase inhibitor | 0.063 0.038 DBMET03266 0.063 0.038 DBMET03267 0.063 0.038 DBMET03268 0.063 0.038 DBMET03269 | ||
| 0.088 | 0.065 | 0.088 | Hepatocyte growth factor antagonist | 0.088 0.065 DBMET03266 0.088 0.065 DBMET03267 0.088 0.065 DBMET03268 0.088 0.065 DBMET03269 | ||
| 0.043 | 0.021 | 0.043 | Glutamate (mGluR group II) antagonist | 0.043 0.021 DBMET03266 0.043 0.021 DBMET03267 0.043 0.021 DBMET03268 0.043 0.021 DBMET03269 | ||
| 0.091 | 0.069 | 0.091 | Phosphodiesterase 7B inhibitor | 0.091 0.069 DBMET03266 0.091 0.069 DBMET03267 0.091 0.069 DBMET03268 0.091 0.069 DBMET03269 | ||
| 0.086 | 0.066 | 0.086 | Phosphodiesterase I inhibitor | 0.086 0.066 DBMET03266 0.086 0.066 DBMET03267 0.086 0.066 DBMET03268 0.086 0.066 DBMET03269 | ||
| 0.034 | 0.015 | 0.034 | Glutamate (mGluR2) antagonist | 0.034 0.015 DBMET03266 0.034 0.015 DBMET03267 0.034 0.015 DBMET03268 0.034 0.015 DBMET03269 | ||
| 0.06 | 0.047 | 0.06 | Phosphodiesterase VII inhibitor | 0.06 0.047 DBMET03266 0.06 0.047 DBMET03267 0.06 0.047 DBMET03268 0.06 0.047 DBMET03269 | ||
| 0.041 | 0.028 | 0.041 | Factor XIa inhibitor | 0.041 0.028 DBMET03266 0.041 0.028 DBMET03267 0.041 0.028 DBMET03268 0.041 0.028 DBMET03269 | ||
| 0.055 | 0.043 | 0.055 | Adenosine A1 receptor antagonist | 0.055 0.043 DBMET03266 0.055 0.043 DBMET03267 0.055 0.043 DBMET03268 0.055 0.043 DBMET03269 | ||
| 0.102 | 0.093 | 0.102 | MAP kinase kinase inhibitor | 0.102 0.093 DBMET03266 0.102 0.093 DBMET03267 0.102 0.093 DBMET03268 0.102 0.093 DBMET03269 | ||
| 0.081 | 0.073 | 0.081 | NADH dehydrogenase inhibitor | 0.081 0.073 DBMET03266 0.081 0.073 DBMET03267 0.081 0.073 DBMET03268 0.081 0.073 DBMET03269 | ||
| 0.091 | 0.084 | 0.091 | Adenylate kinase inhibitor | 0.091 0.084 DBMET03266 0.091 0.084 DBMET03267 0.091 0.084 DBMET03268 0.091 0.084 DBMET03269 | ||
| 0.027 | 0.022 | 0.027 | Purinergic P2Y15 antagonist | 0.027 0.022 DBMET03266 0.027 0.022 DBMET03267 0.027 0.022 DBMET03268 0.027 0.022 DBMET03269 | ||
| 0.026 | 0.022 | 0.026 | Glucosylceramidase stimulant | 0.026 0.022 DBMET03266 0.026 0.022 DBMET03267 0.026 0.022 DBMET03268 0.026 0.022 DBMET03269 | ||
| 0.036 | 0.032 | 0.036 | Vascular adhesion protein 1 inhibitor | 0.036 0.032 DBMET03266 0.036 0.032 DBMET03267 0.036 0.032 DBMET03268 0.036 0.032 DBMET03269 | ||
| 0.084 | 0.081 | 0.084 | MAP kinase kinase 1 inhibitor | 0.084 0.081 DBMET03266 0.084 0.081 DBMET03267 0.084 0.081 DBMET03268 0.084 0.081 DBMET03269 | ||
| 0.093 | 0.09 | 0.093 | GABA C receptor antagonist | 0.093 0.09 DBMET03266 0.093 0.09 DBMET03267 0.093 0.09 DBMET03268 0.093 0.09 DBMET03269 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |